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EXPLANATORY  MEMORANDUM  AND  REPORT  TO  THE  COUNCIL 
I.  GENERAL  CONSIDERATIONS 
1.  In  January  1990,  the  Commission  sent  the  Councl I  and  the  European 
Pari lament  three  proposals  for  directives concerning  the  rational  use 
of medicinal  products  (C0M(89)607  final  of  26.1 .1990),  thus  completing 
the  program  announced  In  the White  Paper  In  1985.  These  consist  of 
proposals  concerning: 
-wholesale distribution of medicinal  products  for  human  use, 
- legal  status for  the  supply of  medicinal  products  for  human  use, 
- label I lng  and  package  leaflets of medicinal  products  for  human  use. 
2.  Although  the  present  proposal  concerning  pharmaceutical  advertising 
was  not  expl lcltly  Included  In  1985  In  the  White  Paper  program,  it 
nevertheless  fa I Is  within  the  same  framework.  The  proposal  In  fact 
alms  to promote  the  rational  use of  medicinal  products  and  also  to 
harmonize  national  legislation  In  this area,  Insofar  as  It  Is 
necessary  for  the  completion of  the  Internal  Market. 
II.  REGULATION  OF  PHARMACEUTICAL  ADVERTISING  IN  THE  MEMBER  STATES 
3.  The  pharmaceutical  Industry on  average  devotes  between  12  and  15%  of 
Its  turnover  to advertising  and  medicinal  Information  (of  which  more 
than  2/3 goes  on  medical  sales  representatives,  in  the  case of 
products  suppl led  on  prescription). 
4.  AI  I  Member  States of  the  Community  have  adopted  specific rules 
concerning  pharmaceutical  advertising over  and  beyond  the  general 
measures  concerning misleading or  unfair  advertising.  These  rules 
always  distinguish  between  advertising  to  the  general  publ lc  and 
advertising or  Information  Intended  for  health professionals. 
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5.  With  regard  to advertising  to  the  general  publ lc,  alI  the  Member 
States  forbid  advertising of  prescription only  medicinal  products. 
Furthermore,  several  Member  States  (Belgium,  Ireland,  United  Kingdom, 
Spain,  Portugal  and  the German  Federal  Republ lc)  prohibit  the 
advertising of  medicinal  products  aimed  at  treating certain particular 
I I lnesses/condltlons.  Where  It  Is  authorised,  pharmaceutical 
advertising  to  the  general  publ lc must  conform  to certain positive 
conditions  (minimum  content)  and  negative  conditions  (prohibition of 
certain  forms  of  advertising). 
In  most  Member  States,  advertising  through  certain media  (T.V.,  Radio) 
Is  subject  to  further  specific control.  Certain Member  States 
(Belgium,  Denmark)  prohibit  alI  pharmaceutical  advertising  through 
these media.  In  this regard,  It  should  be  noted  that  Directive 
89/552/EEC  concerning  television broadcasting activities provides,  in 
Article  14,  for  the  prohibition  television advertising of  medicinal 
products  aval table only  on  prescription  In  the  Member  State within 
whose  area of  competence  the  broadcasting  authority  Is situated. 
Article  3  of  this Directive  however  provides  that  Member  States may, 
with  regard  to broadcasting authorities situated within  their  area of 
competence,  provide  far  stricter or  more  detal led  rules  In  the  areas 
covered  by  this directive. 
6.  National  regulations  concerning  Information  sent  out  to  health 
Professionals  by  pharmaceutical  companies  are  less divergent.  It  is 
almost  always  provided  that  the  Information  sent  out  must  be  either  In 
accordance with  the  Information  to be  found  In  the  summary  of  product 
characteristics,  or  must  reproduce  exactly  this  Information.  The 
majority of  Member  States have  Imposed  restrictions on  the 
distribution of  free  samples. 
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7.  With  regard  to  the monitoring of  pharmaceutical  advertising  three 
different  approaches  are  adopted  (the monitoring of  TV/radio 
advertising being  subject  to  further  specific control  as mentioned 
above). 
In  certain Member  States  (Federal  Republ lc of  Germany,  Belgium, 
Luxembourg)  pharmaceutical  advertising  Is  subject  to a  posteriori 
control  by  the  courts and  tribunals. 
In  other  Member  States  (United  Kingdom,  Ireland,  Netherlands) 
monitoring of  pharmaceutical  advertising  Is  undertaken  prlmarl ly  by 
self  regulatory  bodies. 
Finally,  In  several  Member  States  (Denmark,  France,  Portugal,  Spain, 
Italy)  alI  advertising must  be  approved  In  advance  by  the  competent 
authorities  (In general  the authorities charged with  health matters). 
It  should  be  noted  that  In  Greece  alI  pharmaceutical  advertising  to 
the general  public  Is  In  fact  prohibited so  that  monitoring of 
advertising  Is  not  necessary. 
I I I.  NEED  FOR  A COMMUNITY  DIRECTIVE 
8.  The  Community  is competent  to adopt  alI  measures  necessary  for  the 
completion of  the  internal  market,  which  consists of  an  area  without 
Internal  frontiers where  the  free movement  of  goods,  persons,  services 
and  capital  Is  ensured.  As  the Court  of  Justice emphasized  In  its 
Judgment  of  6  March  1990  (case  GB-INNO-BM  v.  CCL),  the  divergence  In 
national  laws  restricting or  prohibiting certain  forms  of  advertising 
Is  capable of  hindering  the  free  movement  of  goods,  by  affecting  the 
access of  goods  to  the  market.  Harmonization  of  national  laws 
concerning  pharmaceutical  advertising  Is  therefore  necessary  In  so  far 
as  differences  In  the specific rules  relating  to  this  form  of 
advertising  I lmlt  the  free movement  of  pharmaceuticals. 
9.  AI  I  Member  States of  the Community  have  Indeed  adopted,  alongside with 
the  general  rules  concerning advertising,  specific measures  In  respect 
of  pharmaceutical  advertising.  Though  based on  common  principles, 
these measures  present  significant  divergences. - 4  -
10.  The  harmonisation of  the measures  taken  by  the Members  States would 
also appear  necessary  to ensure  the  freedom  to  provide advertising 
services.  In  fact,  pharmaceutical  companies  wi  I I  undoubtedly  take more 
and  more  advantage of  the  posslbl I lty  already open  to  them  In 
Community  law  of  marketing medicinal  products  In  a  member  State 
without  being establ lshed or  represented  there.  Thus  numerous 
advertisements  wl  I I  be  conceived  and  transmitted  In  one  Member  State 
and  destined  for  people  In  another  Member  State.  Furthermore,  given 
the  Integration of  markets,  in  particular  In  the context  of  the  future 
system  of  authorisation of medicinal  products,  advertising campaigns 
wll I  be  conceived  In  such  a  way  as  to cover  several  Member  States at 
one  time. 
11.  It  Is  therefore  necessary  to establIsh a  common  framework  for 
pharmaceutical  advertising as  wei I  as  providing  for  certain 
requirements  to which  pharmaceutical  advertising must  conform  where  It 
Is  authorised,  In  such  a  way  that  alI  pharmaceutical  advertising 
transmitted within  the  Community  fulfi I Is  certain essential  criteria, 
no  matter  to whom  It  Is  addressed within  the Community. 
IV.  CONTENTS  OF  THE  PROPOSAL 
12.  With  the exception of  certain common  principles and  general ltles 
(Article  2)  the  proposal  for  a  directive provides  for  separate systems 
for  advertising  to  the general  publ lc  and  advertising  to health 
professionals. 
13.  Under  a  principle  common  to alI  Member  States,  advertising  to  the 
general  public can  only  be  permitted where  It  concerns  products  for 
self-medication:  advertising  to  the public of  medicinal  products 
obtainable only  by  prescription should  therefore,  by  reference  to  the 
recent  Commission  proposal  on  the  legal  status of  the supply of 
medicinal  products  Intended  for  human,  be  prohibited  (Article 3). - 5  -
In  cases where  advertising  to  the general  publ lc  Is permitted,  It  must 
comply  with  certain positive  (Article 4)  and  negative  (Article 5) 
conditions. 
14.  Advertising addressed  to  health  professionals must  Include  more 
extensive  Information  than  that  addressed  to  the general  pubt lc 
(Article 6).  In  fact  advertising  to  health  professionals must  enable 
the  addressee  to  form  his own  opinion of  the  therapeutic worth  of  the 
medicinal  product;  these principles also apply  to  the  documentation 
provided with  regard  to  promotion  of medicinal  products  (Article 7). 
Medical  sales  representatives are  thus  assigned  a  positive role and 
they must  supply  a  summary  of  product  characteristics  for  each  of  the 
products  they  promote,  and  report  certain pharmacovl I lgl lance 
Information  to  the  firm  employing  them.  Furthermore,  the objective 
Information  of  doctors and  pharmacists  Is  Incompatible  with  financial 
Inducements  of whatever  nature,  and  as  such  should  be  prohibited 
(Article 9).  Final Jy,  even  though  samples  of  medicinal  products  at low 
doctors  and  pharmacists  to  famllarlse  themselves  with  new  medicinal 
products,  the  conditions under  which  such  samples  can  be  suppl led 
should  be  I lmtted  (Article 10). 
15.  Measures  concerning  the monitoring of  pharmaceutical  advertising are 
to a  large extent  drawn  from  the  system of  Directive 84/450/EEC 
concerning misleading advertising.  Thus  the  rote of  self-regulatory 
bodies  Is expressly  recognised  (Article 11).  As  a  means  of 
guaranteeing  the  principles  laid  down  by  the  Directive,  pharmaceutical 
companies  are  required  to establIsh within  the  company  a  Scientific 
Service,  which  would  act  as  a  point  of  contact  for  at I  scientific 
Information  concerning  the medicinal  products of  the  company 
(Article  12). - 6  -
V.  CONCLUSIONS 
16.  This  proposal  has  been  the  subject  of  several  rounds  of  consultations 
since July  1989  with  the directors of  pharmacy  within  the 
pharmaceutical  Committee  (July,  October  and  December  1989),  with 
European  associations  representing  the  pharmaceutical  Industry, 
advertisers,  consumers  and  the medical  and  pharmaceutical  professions. 
17.  In  accordance  with  the  requirements of  Articles  SA  and  SC  of  the 
Treaty establ lshlng  the  European  Economic  Community,  the Commlssl.on 
requests  the  Member  States to  take  the measures  necessary  to comply 
with  this proposal  by  1  January  1992. 
The  Commission  has  taken  Into  account  the  requirements  of  Article  SC 
of  the Treaty  and  has  concluded  that  no  special  provision seems  to be 
justified at  this stage. 
The  Commission  has  also studied  the  question  from  highest  level  of 
health,  safety,  environmental  and  consumer  protection  required  by  the 
terms  of  Article 100  A,  paragraph.3.  It  has  done  so  following 
consultation of  the  Industrial  and  social  partners concerned,  and  In 
the  I lght  of  an  analysts of  the  current  technical  capabl I ltles of  the 
European  Industry.  The  proposals  take  ful I  account  of  these 
considerations  In  the  I lght  of  the overal I  objectives of  this 
provision of  the Treaty. -1-t 
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THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the  Treaty establishing  the  European 
Economic  Community,  and  in  particular  Article  IOOa 
thereof, 
Having  regard  to  the  proposal  from  the  Commission, 
In  cooperation with the European Parliament, 
Having  regard  to  the  opinion  of  the  Economic  and 
Social  Committee, 
Whereas  Council  Directive  84/450/EEC (')  has 
harmonized  the  laws,  regulations  and  administrative 
provisions of the  Member States  concerning  misleading 
advertising; 
Whereas all  Member States have  adopted further specific 
measures  concerning  the  advertising  of  medicinal 
products;  whereas  there  are  disparities  between  these 
measures; whereas these disparities are likely to have  an 
impact  on  the  establishment  and  functioning  of  the 
internal  market,  since  advertising  disseminated  in  one 
Member State  is  likely  to have effects  in  other Member 
States; 
Whereas  Council  Directive  89/552/EEC of 3  October 
1989 on the coordination of certain provisions laid down 
by  law,  regulation  or administrative  action  in  Member 
States  concerning  the  pursuit of television  broadcasting 
activities  (')  prohibits  the  television  advertising  of 
medicinal products which  are available  only on medical 
prescription  in  the  Member  State  within  whose  juris-
diction the television broadcaster is  located; whereas this 
principle should be made of general application by prohi-
biting  all  advertising  of  medicinal  products  which  are 
available  only on prescription; 
Whereas  advertising  to  the  general  public  even  of 
non-prescription  medicinal  products  could  affect  public 
(')  OJ No L 250,  19.  9.  1984,  p.  17. 
(')  OJ  No L 298,  17.  10.  1989, p  23. 
health,  if  it  was  excessive  and  ill-considered;  whereas 
advertising  of medicinal  products  to  the  general  public, 
where  it  is  permitted,  ought therefore  to  satisfy  certain 
essential criteria which ought to  be  defined; 
Whereas,  furthermore,  distribution  of  samples  free  of 
charge to the  general public  for  promotional ends  must 
be prohibited; 
Whereas the advertising of medicinal products to persons 
qualified to prescribe  or supply  them  contributes  to  the 
information  available  to  such  persons;  whereas,  never-
theless  this  advertising  should  be  subject  to  strict 
conditions  and  effective  monitoring,  referring  in 
particular to the work achieved within the framework of 
the Council of Europe; 
Whereas medical sales representatives  have an  important 
role  in  the  promotion  of  medicinal  products;  whereas 
therefore  certain  obligations  should  be  imposed  upon 
them  in  particular  the  obligation  to  supply  the  person 
visited  with  a summary of product characteristics; 
Whereas  persons  qualified  to  prescribe  medicinal 
products must be able to carry out these functions objec-
tively  without  being  influenced  by  direct  or  indirect 
financial  inducements; 
Whereas  it  should  be  possible  within  certain  restncuve 
conditions to provide samples of medicinal products free 
of  charge  to  persons  qualified  to  prescribe  or  supply 
them  so  that  they  can  familiarize  themselves  with  new 
products  and  acquire  experience  in  dealing  with  them; 
Whereas  persons  qualified  to  prescribe  or  supply 
medicinal  products  must  have  access  to  a  neutral 
objective source of information about products available 
on the market; whereas it is  nevertheless for the Member 
States to take all  measures necessary to this end, in  light 
of their own  particular situation; 
Whereas  advertising  of  medicinal  products  should  be 
subject  to  effective,  adequate  monitoring;  whereas 
reference  in  this  regard  should  be  made  to  the  moni-
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Whereas  each  undertaking  which  manufactures  or 
imports medicinal products should set up a mechanism to 
ensure  that  all  information  supplied  about  a  medicinal 
product conforms  with  the  approved conditions of use, 
HAS  ADOPTED THIS DIRECTIVE: 
CHAPTER I 
Scope,  defmitions  and  general principles 
Article 1 
1.  This Directive concerns the advertising of medicinal 
products for human use  in  the Community. 
2.  For the purposes of this  Directive, 
the definition of 'advertising' shall be  that laid down 
in Article 2 of Direqive 84/  450/EEC, 
- the definition of 'medicinal product' shall be that laid 
down  in  Article  1  of  Council  Directive 
65/65/EEC C), 
the definitions of the 'name of the medicinal product' 
and of the  'common name' shall  be  those laid down 
in Article 1 of Council Directive .. ./  .. ./EEC, 
the  'summary of product characteristics' shall  be  the 
summary approved by the competent authority which 
granted  the  marketing  authorization  in  accordance 
with Article 4b of Directive 65/65/EEC. 
3.  For  the  purposes  of  the  application  of  this 
Directive, the advertising of medicinal products includes, 
in  particular: 
information  of a  commercial  nature  for  health  care 
professionals, in whatever form, which may promote 
the prescription or supply of medicinal products, 
- visits by medical representatives to persons allowed to 
prescribe or supply medicinal products, 
any  incitement  to  prescribe  or  supply  medicinal 
products by  the gift,  offer or promise of any benefit 
or  bonus,  whether  in  money  or in  kind,  including 
invitations to travel or to congresses. 
Article 2 
1.  Any advertising of a medicinal product in respect of 
which a marketing authorization has not been granted in 
accordance with Community law is  prohibited. 
(')  OJ No L 22,  9.  2.  1965,  p.  369/65. 
2.  All  parts of the  advertising of a  medicinal product 
must  be  compatible  with  the  particulars  listed  in  the 
summary of product characteristics. 
3.  The advertising of a  medicinal product: 
shall  encourage  the  rational  use  of  the  medicinal 
product,  by  presenting  it  objectively  and  without 
exaggerating its properties, 
shall  not  be  misleading,  within  the  meanmg  of 
Directive 84/  450/EEC. 
CHAPTER II 
Advertising  to  the  general  public 
Article 3 
1.  Member States shall  prohibit the  advertising to the 
general public of: 
medicinal  products  which  contain  psychotropic  or 
narcotic substances, within the meaning of the inter-
national conventions, 
other medicinal products which are only available on 
prescription,  in  accordance  with  Council  Directive 
.. ./  .. ./EEC. 
2.  Member States shall prohibit the mention in  adver-
tising to the general public of therapeutic indications for 
which  self-medication  is  not suitable,  in  particular: 
- tuberculosis, 
sexually transmitted diseases, 
other serious infectious diseases, 
-cancer, 
- chronic insomnia, 
- diabetes and other metabolic illnesses. 
3.  The prohibition referred to in paragraph 1 shall not 
apply  to  vaccination  campaigns  approved  by  the 
competent authorities of the  Member States. 
4.  The prohibition referred in paragraph 2 shall apply 
without  prejudice  to  Articles  2,  3  and  14  of Directive 
89/552/EEC. 
5.  Member States shall prohibit the free distribution of 
medicinal  products  to  the  public  for  promotional 
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Article 4 
Without  prejudice  to  Article  3,  all  advertising  to  the 
general public of a  medicinal product shall: 
(a)  be  set out in  such a fashion  that it is  clear that the 
message  is  an advertisement, and that the product is 
dearly identified as a medicinal product; 
(b)  include the following minimum information: 
the name of the medicinal product, incorporating 
or  followed  by  the  common  name  if  the 
medicinal  product  contains  only  one  active 
ingredient, 
- the  information  necessary  for  correct  usage  of 
the medicinal product, such as  indications for use 
and  special  precautions,  or,  failing  this,  an 
express  invitation  to  read . the  package  leaflet 
carefully. 
Article 5 
The  advertising  of a  medicinal  product to  the  general 
public shall not contain any material which: 
(a)  gives  the  impression  that a  medical  consultation  or 
surgical  operation  is  unnecessary,  in  particular  by 
offering  a  diagnosis  or by  suggesting  treatment  by 
mail; 
(b)  suggests  erroneously  that the  effects  of taking  the 
medicine are guaranteed, or are better than another 
treatment; 
(c)  suggests  that the normal good health of the subject 
can be  enhanced by taking  the  medicine,  or that it 
could be affected by not taking the medicine; 
(d)  is  directed solely or mainly at children; 
(e)  refers  to  a  recommendation  by  scientists  or health 
professionals; 
(f)  suggests that the medicinal product is  a foodstuff or 
a cosmetic, or vice versa; 
(g)  suggests thiu the safety or efficacy of the medicinal 
product is due to the fact that it is 'natural'. 
CHAPTER III 
Advertising to health professionals 
Article 6 
1.  Any advertising -of  a  medicinal  product to persons 
qualified  to  prescribe  or  supply  such  products  shall 
include: 
the  particulars  listed  m  the  summary  of  product 
characteristics, 
- the legal prescription status of the medicinal product, 
the retail price of the various presentations, 
if  appropriate,  conditions  of coverage  by  the  social 
security systems. 
2.  The  adverti~ing of a  medicinal  product to persons 
qualified  to  prescribe  or  supply  such  products  may, 
notwithstanding paragraph  1,  include  only the name of 
the medicinal product, if its  sole object is  to recall to the 
latter. 
Article  7 
1.  Any documentation relating to a medicinal product 
which  is  transmitted  as  part  of the  promotion  of that 
product  to  persons  qualified  to  prescribe  or supply  it 
shall  include  as  a  minimum  the  particulars  listed  in 
Article 6  (1). 
2:  All  the information contained in the documentation 
referred to in  paragraph  1 shall be  accurate, up-to-date, 
verifiable  and  sufficiently  complete  to  enable  the 
recipient to  form  his  or her own  opinion  of the  thera-
peutic value  of the  medicinal  product concerned. 
3.  Quotations  as  well  as  tables  and other illustrative 
matter  taken  from  medical  journals  or other scientific 
works  for  use  in  the  documentation  referred  to  in 
paragraph  1  shall  be  faithfully  reproduced  and  the 
precise sources indicated. 
Article 8 
1.  Medical  sales  representatives  shall  be  given 
adequate  training  and  shall  have  sufficient  scientific 
knowledge  to  be  able  to  provide  precise  and  complete 
information  about  the  medicinal  products  which  they 
promote. 
2.  During each visit, medical sales representatives shall 
provide  the  persons  visited  with  the  summaries  of 
product  characteristics  in  respect  of  each  medicinal 
product which they present. 
3.  Medical  sales  representatives  shall  transmit  to the 
scientific service  referred to in  Article  12  (1),  any infor-
mation  about  the  use  of the  medicinal  products  they 
promote,  especially  about  adverse  reactions,  that  is 
reported to them by the  persons they visit. 
Article  9 
1.  In  the  course of promoting  medicinal  products  to 
persons qualified to prescribe them, it shall be prohibited 
to give,  proffer or promise to such persons,  directly or 
indirectly,  any gifts,  pecuniary advantages or benefits  in 
kind,  with  the  exception  of objects  of an  insignificant 
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2.  Persons  qualified  to prescribe  or supply  medicinal 
products  shall  not  solicit  or  accept  any  inducement 
prohibited under paragraph 1. 
3.  The prohibition referred to in  paragraph  1 applies 
without  prejudice  to  the  regulations  of  the  Member 
States  concerning  prices,  profit  margins  and  discounts. 
Article 10 
Where  medicinal  products  are  being  promoted  to 
persons  qualified  to  prescribe  or  supply  them,  free 
samples  shall  be  provided  to such  persons  only on  the 
following conditions: 
(a)  two samples at the most may be provided every year 
to  any  person  qualified  to  prescribe  or  to  supply 
medicinal products; 
(b)  any  supply  of  samples  must  be -in  response  to  a 
written request, signed and dated, of the recipient; 
(c)  the samples shall be  identical to the smallest presen-
tation on the market; 
(d)  the samples shall be marked 'free medical sample -
not for resale' or with another legend of analogous 
meamng; 
(e)  the  samples  shall  be  accompanied by a  copy of the 
summary of product characteristics; 
(f)  no samples of medicinal products containing psycho-
tropic or narcotic substances within the meaning of 
international conventions may be supplied. 
CHAPTER IV 
Monitoring of advertising 
Article  11 
1.  Member States shall ensure that there are adequate 
and  effective  methods  to  monitor  advertising  of 
medicinal  products.  Such  methods  shall  include  legal 
prov1s1ons  under  which  persons  or  organizations 
regarded  under  national  law  as  having  a  legitimate 
interest  in  prohibiting  any  advertisement  inconsistent 
with  this  Directive  may  take  legal  action  against  such 
advertisement,  or  bring  such  advertisement  before  an 
administrative  authority  competent  either  to  decide  on 
complaints  or to  initiate  appropriate  legal  proceedings. 
2.  Under the legal provisions referred to in paragraph 
1,  Member States shall confer upon the courts or admin-
istrative authorities powers enabling them: 
to order the discontinuance, correction or withdrawal 
of any advertisement inconsistent with this Directive, 
require  either the  publication  of a  corrigendum,  or 
the  publication  in  whole  or in  part  and  in  a  form 
which  it  shall  deem  adequate,  of  the  decision 
ordering-the discontinuance of an advertisement. 
3.  Under the legal provisions referred to in paragraph 
1,  Member States shall ensure that any decision taken in 
accordance  with  paragraph  2  shall  state  in  detail  the 
reasons on which it is  based and shall be communicated 
in  writing  to  the  person  concerned,  mentioning  the 
remedies available at law and the time limit allowed for 
the exercise of such remedies. 
4.  This Article  shall  not exclude voluntary control of 
advertising  of  medicinal  products  by  self-regulatory 
bodies and recourse to such bodies, if proceedings before 
such  bodies  are  in  addition to  the  judicial  or adminis-
trative proceedings referred to in  paragraph  1. 
Article  12 
1.  The person responsible for marketing shall establish 
within  his  undertaking  a  scientific  service  in  charge  of 
information  about  the  medicinal  products  which  he 
places  on the market. 
2.  The person responsible for marketing shall: 
make  available  to  the  bodies  responsible  for  moni-
toring advertising of medicinal products a  sample of 
all  advertisements  emanating from  their undertaking 
together with  a  statement indicating  the persons  to 
whom  it  is  addressed,  the  method  of dissemination 
and the date of first dissemination, 
ensure  that advertising of medicinal  products by his 
undertaking  conforms  to  the  requirements  of  this 
Directive, 
- verify that medical sales  representatives employed by 
his  undertaking  have  been  adequately  trained  and 
fulfil  the obligations imposed upon them by Article 8 
(2) and (3), 
supply the bodies responsible for monitoring pharma-
ceutical  advertising  of  medicinal  products  with  the 
information and assistance these require to carry out 
their responsibilities, 
ensure that the decisions taken by the bodies charged 
with  monitoring  advertising  of  medicinal  products 
are immediately and fully complied with. 
Article 13 
1.  Where  the  provisions  of  the  Directive  have  not 
been observed, and a warning notice served on the party 
concerned  has  remained  without  effect,  the  competent 
authorities of a  Member State may suspend the authori-
zation  to  market  the  medicinal  product  concerned, 
without  prejudice  to  any other sanction  which  may be 
applied  under national law. -l[-; 
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2.  All  decisions  taken  pursuant to  paragraph  1  shall 
state  in  detail  the  reasons  on which  they are  based.  A 
decision shall be notified to the party affected by it, who 
shall  at  the  same  time  be  informed  of  the  remedies 
available  at  law  and  the  time  limit  allowed  for  the 
exercise of such remedies. 
Article  14 
Member States  shall  take all  the steps  necessary to 
comply with  this  Directive  with  effect  from  1 January 
1992.  They  shall  forthwith  inform  the  Commission 
thereof. 
2.  Measures  taken  in  accordance  with  paragraph 
shall make express  reference to this  Directive. 
Article  15 
This Directive  is  addressed to the Member States. COMPETITIVENESS  AND  EUPLOYUENT  IUPACT  STATEUENT 
relating  to  the  proposal  for  a  directive 
concerning  the  advertising of  medicinal  products  for  human  use 
1.  What  Is  the main  reason  for  Introducing  the measures? 
Completion of  the  internal  market;  improvement  of  the  protection of 
publ lc  health;  promotion  of  the  rational  use  of  medicinal  products; 
Information of  consumers  and  of  health  professionnals. 
11.  Features of  the businesses  In  question? 
Because of  the  high  costs of  developplng  new  products,  pharmaceutical 
entreprlses are often  large  companies  (multinational  or  national).  There 
are,  however,  some  smaller  and  medium  sized manufacturers  geared  at  the 
national  market. 
II 1.  What  direct obligations do  these measures  Impose  on  businesses? 
-Obi igation  to  conform  with  the  rules  relating  to advertising  to  the 
general  public  :  the  proposed  measures  harmonize  existing national 
rules which  are  themselves  quite stricvt  (hence,  no  additional  cost-
rationalization of  advertising  campaigns  througout  the  Community). 
-Obi lgation  to deliver  systematically  the  summary  of  products 
characteristics  :  marginal  additional  cost. 
Obi igation  to establish  a  scientific service  In  charge of  medical 
Information  :almost  every  undertaking  already  has  such  a  service 
(which,  as  the  cas  may  be,  could  consist  of  just  one  person). IV.  What  Indirect obligations are  local  authorities  I l~ely to  Impose  on 
buslnessess  ? 
None. 
V.  Are  there any  special  measures  In  respect of  SMEs  ? 
No. 
VI.  What  Is  the  ll~ely effect on 
a)  the competitiveness of business  • 
The  proposed  measures  wi  I I  put  pharmaceutical  undertakings on  equal 
conditions,  Irrespective of  the  location of  their  establishment  in 
the  Community  and  of  the  destinee of  the  advertising. 
b)  employment  ? 
No  significant effect  is  anticipated. 
VII.  Have  both sides of  Industry been  consulted on  these proposals? 
Following  interested parties were  consulted 
-associations representing  consumers, 
-associations of  the  pharmaceutical  industry, 
-associations of  advertisers, 
-associations of  pharmacists, 
-associations of  doctors  and  other  health  professionals. -ri-
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